Dr. Moghimi is developing next-generation CAR T-cells to treat pediatric AML.
Acute Myeloid leukemia (AML) is the second most common leukemia in children, and the prognosis after relapse is poor. Unlike current CAR T treatment for the most common childhood leukemia, acute lymphoblastic leukemia (ALL), patients with AML experience significant toxicity […]
Dr. Moghimi is developing next-generation CAR T-cells to treat pediatric AML. Read More »